| Bioactivity | NRC-2694-A is an orally effective EGFR tyrosine kinase inhibitor. NRC-2694-A can be used in the study of malignant squamous cell carcinoma (HNSCC)[1]. |
| CAS | 1172626-99-1 |
| Formula | C24H27ClN4O3 |
| Molar Mass | 454.95 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Adkins D, et al. Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial. 2023. |
NRC-2694-A
CAS: 1172626-99-1 F: C24H27ClN4O3 W: 454.95
NRC-2694-A is an orally effective EGFR tyrosine kinase inhibitor. NRC-2694-A can be used in the study of malignant squam
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.